YD Bio Limited

11/11/2026

Know your risk. Know the factors. 💜

Understanding what’s linked to pancreatic cancer is a simple first step toward a better conversation with your doctor.

Factors linked to a higher chance of pancreatic cancer include:
・Smoking, one of the most important risk factors you can change
・Excess weight
・Diabetes, especially long-standing or starting after 50
・A parent, sibling or child with pancreatic cancer
・Chronic pancreatitis, a long-term inflammation of the pancreas
・Age, as risk rises when we get older

Having a risk factor doesn’t mean you will get pancreatic cancer. But the more that apply, the more reason to talk to your doctor.

Take a moment to go through the list, and share it with someone you care about.

11/06/2026

Your pancreas works hard every day, and most of us rarely think about it. 💜
Here are its two main jobs:

1️⃣ A digestive juice factory
It makes enzymes that break down carbs, fats and proteins. The protein-digesting ones only switch on once they reach the intestine, so the pancreas doesn’t digest itself. Its juice also carries bicarbonate, which neutralizes stomach acid so the enzymes can do their job.

2️⃣ A blood sugar seesaw
After meals, insulin brings blood sugar down. Between meals, glucagon brings it back up. Together, they keep your levels steady all day.

How many of these did you already know? Tell us in the comments, and share this with someone you care about.

10/31/2026

2027 is coming — and we’re stepping into it together. 🕶️✨

A huge thank you to the EG BioMed team for including us in this one. Here’s to the people behind the science — and everything we’ll build together in the year ahead.

To our teams on both sides: thank you for everything this year. See you in 2027. 🙌

🎬 Watch the video: https://youtube.com/shorts/cwkZnG6Rz1Y?is=rSmGGDv6-4V2upRE

#2027

A big thank you to our team for a year of hard work and dedication!...

10/31/2026

We put a lot of effort into managing our health — steps, sleep, calories. We know our bodies better than ever. But there’s one question most people have never really stopped to ask: How high is my cancer risk?

Most health tools show you how you’re doing today. Few help you see what’s coming.

The AI Cancer Risk Assessment was built to answer exactly that question — and through JoiiUp, it’s now part of corporate employee wellness programs.

🏥 Developed with 3 TMU-affiliated hospitals
🔬 Validated against 1,227 clinical records
🎯 Covers 10 cancer types
🧪 Backed by a CLIA- and CAP-certified laboratory
📱 Available via JoiiSports App — 400+ companies, 12+ years

📌 This assessment is for reference only. Please consult a healthcare professional for medical advice.

10/23/2026

What does YD Bio actually do?
We’re a Nasdaq-listed biotech building an integrated healthcare platform across five business lines.

🔬 Cancer Detection | OkaiDx™ DNA methylation blood tests; CLIA/CAP-certified lab; 47 U.S. states; physician-ordered
👁 Ocular Products | Exovisse™ (FDA 510(k)), available nationwide
🧬 Ocular Therapeutics | LSC exosome therapy in development; DMF filed with FDA
📋 Regulatory Services | U.S. FDA agent for Asian pharma clients
🌿 Consumer Health | Physician-partnered nutraceuticals launched Taiwan, Aug 2026

This is what building a healthcare platform looks like.

🔗 ir.ydesgroup.com

10/21/2026

We’re excited to announce a new strategic partnership with EG BioMed and JoiiUp — bringing AI-powered cancer risk assessment directly into corporate wellness programs.

Together, we’ve integrated the AI Cancer Risk Assessment into JoiiUp’s JoiiSports app — a platform already trusted by over 400 companies and backed by 12+ years of workplace health experience.

What makes this different:
✅ Validated using 1,200+ clinical records in collaboration with 3 TMU-affiliated hospitals
✅ Covers 10 cancer types through an online questionnaire — no blood draws, no imaging
✅ Delivers personalized risk reports and lifestyle recommendations via SSO directly in the JoiiSports app

This is the first step in building a comprehensive cancer management pathway — from awareness to early action.

This tool provides personalized health guidance for reference purposes only. It is not intended for cancer diagnosis — we encourage users to discuss results with a qualified healthcare professional.

Learn more → https://pse.is/9s2xe3

10/16/2026

”I'm too young to worry about this."

That might be one of the most common misconceptions about breast cancer.

According to the American Cancer Society, about 1 in 10 breast cancer diagnoses occur in women under 45. And the cancers that develop in younger women tend to be more aggressive — with higher rates of triple-negative and HER2-positive subtypes, and generally worse outcomes.

What's more, incidence rates in women under 50 are rising at 1.4% per year — faster than the overall average.

Contributing factors may include having fewer children, having a first child after 30, and excess body weight. But perhaps the biggest issue is simpler: younger women are less likely to get screened regularly, and more likely to brush off early symptoms — which means diagnoses often come later.

Age is not a shield. 🎗️

10/13/2026

🎗️ October 13 — Metastatic Breast Cancer Awareness Day

Let's not forget the patients living with cancer that has spread — facing their diagnosis with everything they have.

For them, treatment often focuses on extending life, controlling disease progression, and maintaining quality of life, making ongoing post-treatment follow-up and recurrence monitoring especially important. The OkaiDx™ Breast Cancer Monitoring blood test is offered by YD Bio together with its affiliate EG BioMed, through EG BioMed's CLIA/CAP-certified U.S. laboratory, analyzing cfDNA methylation to help track post-treatment changes.

Today, let's see them, and stand with them.



*For screening and risk-assessment purposes only. Not a diagnostic device.

10/12/2026

Every October, progress in breast cancer research deserves attention.

Cell-free DNA (cfDNA) methylation analysis — it sounds technical, but the idea behind it is surprisingly intuitive.

When cells break down, they release small DNA fragments into the bloodstream. These fragments carry chemical markers called methylation patterns — a kind of molecular fingerprint. By analyzing these patterns, researchers can observe cancer-associated molecular changes in the blood without invasive tissue sampling.

In breast cancer, studying how these molecular markers shift after treatment is an active area of translational research. EG BioMed — an affiliate of YD Bio Limited (Nasdaq: YDES) — supports research in this space through its CLIA/CAP-certified U.S. laboratory, using the OkaiDx™ platform.